Skip to content

Theraclear

by Theravant Corporation

510(k) K101415

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Source FDA 510(k), synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK101415 Date8 Jul 2010ClearedStatusActive

Official records

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

510(k) Number
FDA product code
GEX
Device class
Class II
Regulation
21 CFR Part 878.4810
Advisory committee
General, Plastic Surgery
FDA decision
SESE Substantially Equivalent

Overview

AI-generated summary, 6 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Theraclear is a medical device developed for the treatment of acne. It is classified under the product code GEX. The device is substantially equivalent and has been cleared through the traditional clearance type.

The Theraclear is supplied by Theravant Corporation and has received FDA 510K authorization. It is intended for use in a medical setting, such as a physician's office, and is designed for the in-office treatment of common forms of acne.

Devices cleared under K101415

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under K101415
UDI-DISize and differences
TheraClear TC40
STRATA Skin Sciences, Inc
TC40M709THCLR01 —On the market

Similar devices

Other devices filed under FDA product code GEX (Powered Laser Surgical Instrument).

Other devices from Theravant Corporation

See all devices from Theravant Corporation →